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FUT2 determines whether histo-blood group antigens are 
secreted at mucosal surfaces. Secretor status influences suscep-
tibility to enteric viruses, potentially including oral poliovirus 
vaccine (OPV). We performed a nested case–control study to 
determine the association between FUT2 genotype (single-nu-
cleotide polymorphisms G428A, C302T, and A385T) and sero-
conversion among Indian infants who received a single dose of 
monovalent type 3 OPV. Secretor prevalence was 75% (89 of 
118) in infants who seroconverted and 80% (97 of 122) in infants 
who did not seroconvert (odds ratio, 0.79; 95% confidence 
interval, .43–1.45). Our findings suggest that FUT2 genotype 
is not a key determinant of variation in OPV immunogenicity.
Keywords. Blood group; FUT2; immunogenicity; OPV; 
poliovirus; secretor; vaccine.
 
The efficacy of oral vaccines in low-income countries is less 
than that in high-income countries. Several mechanisms have 
been implicated in this phenomenon, including interference 
by maternal antibodies, enteric pathogens, and environmen-
tal enteropathy [1]. Genetic factors may also be pertinent. In 
particular, the potential influence of histo-blood group antigen 
(HBGA) genotype on oral vaccines has garnered increasing 
interest.
HBGAs are glycans that are present on erythrocytes, on epi-
thelial cells, and in mucosal secretions. The structure of these 
glycans is determined by several key loci. FUT2, for example, 
encodes a fucosyltransferase that modifies HBGAs such that 
they are secreted at mucosal surfaces—whereas individuals 
termed “secretors” have at least 1 functional copy of this gene, 
“nonsecretors” harbor mutations in FUT2 that disrupt enzyme 
function. Notably, nonsecretors exhibit near-complete resis-
tance to infection with P[8] rotavirus or GII.4 norovirus but 
remain susceptible to other genotypes of these enteric viruses 
[2], potentially reflecting genotype-specific HBGA binding.
Secretor status may also contribute to geographic discrepan-
cies in oral vaccine efficacy. Although the frequency of secretors 
is generally comparable across populations in low- and high-in-
come settings (approximately 80%), the implications of being a 
secretor may vary substantially. First, secretor status modifies 
susceptibility to enteric pathogens that display marked varia-
tion in transmission intensity. These enteric pathogens may, in 
turn, influence oral vaccine immunogenicity [3]. Second, the 
structure of secreted HBGAs depends on other genes (eg, ABO 
and FUT3), the alleles of which vary in frequency among pop-
ulations [4]. Studies are starting to elucidate the complex rela-
tionship between HBGA phenotype and oral vaccine response. 
For example, among infants in Pakistan who received 3 doses of 
Rotarix, seroconversion was observed in 19% of nonsecretors, 
30% of secretors with non-O blood groups, and 51% of secre-
tors with blood group O [5]. In Nicaragua, rotavirus vaccine 
immunogenicity was reduced in infants with a Lewis A pheno-
type and was lower in secretors with blood group B than secre-
tors with blood groups A or O [6].
The effect of secretor status on oral poliovirus vaccine (OPV) 
remains untested. We hypothesized that, analogous to the rela-
tionship observed for certain rotavirus and norovirus geno-
types, nonsecretors may be less susceptible to replication of the 
poliovirus vaccine, inhibiting OPV immunogenicity. We tested 
this possibility by examining the association between FUT2 
genotype and vaccine response following a trial of monovalent 
type 3 OPV (mOPV3) in south India.
METHODS
Study Population
We recently performed a randomized, placebo-controlled trial 
to assess the impact of azithromycin on the immunogenicity of 
a single dose of mOPV3 among 754 infants aged 6–11 months 
in Vellore, India (CTRI/2014/05/004588). Details of the design 
and primary outcomes of the trial have previously been pub-
lished [7]. All infants lacked type 3 poliovirus antibodies at 
enrollment. Blood samples were collected 21 days after vacci-
nation to assess seroconversion, and any remaining blood was 
stored at 4°C. In a subset of 300 infants, poliovirus shedding was 
tested 7  days after vaccination. Written informed consent for 
enrollment was obtained from a parent or caregiver. The study 
was approved by the Institutional Review Board of the Christian 
Medical College and the Drugs Controller General of India.
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Here, we report on a nested case–control study performed 
after the completion of this trial. We estimated that the inclu-
sion of 123 serological responders and 123 nonresponders 
would provide 90% power with an α of .05 to detect a 2.5-fold 
increase in the odds of being a secretor among responders 
versus nonresponders, assuming an overall secretor genotype 
prevalence of 70% (based on a previous cohort study in Vellore 
[8]). We increased this sample size to 130 responders and 130 
nonresponders to allow for an assay failure rate of 5% (eg, owing 
to insufficient DNA yield). Infants were considered eligible for 
inclusion if they completed the study per protocol, received pla-
cebo (as opposed to azithromycin), and had at least 500 μL of 
blood available for DNA extraction (n = 312). We prioritized 
infants for whom OPV shedding or bacterial microbiota com-
position had been assessed (as previously described [7, 9]) 
and selected the remaining infants at random (Supplementary 
Figure 1).
FUT2 Genotyping by Real-Time Polymerase Chain Reaction (PCR) Analysis
DNA for FUT2 genotyping was extracted from 500 μL of clot-
ted blood, using the QIAamp DNA Blood Mini Kit. The clot 
was initially broken up with a pipette tip, then incubated with 
500 μL of AL buffer and 20 μL of protease K for 30 minutes at 
50°C. Before column-based purification, 400 μL of this mixture 
was subjected to a second incubation with 400 μL of AL buffer 
and 40 μL of protease K for 10 minutes at 56°C. Eluted DNA was 
stored at −70°C until testing.
In each DNA sample, we assessed 3 single-nucleotide poly-
morphisms (SNPs) that are known to disrupt the function of 
FUT2: G428A (rs601338), a nonsense mutation that is the most 
common cause of the nonsecretor phenotype globally; C302T 
(rs200157007), a missense mutation recently linked with secretor 
phenotype and enterotoxigenic Escherichia coli susceptibility in 
Bangladesh [10]; and A385T (rs1047781), a missense mutation 
that is prevalent in East Asians. The missense mutation G739A 
(rs602662) is also common globally but was found to co-occur 
with G428A in all South Asians in the 1000 Genomes Project 
[11, 12] and was therefore excluded here. Other polymorphisms 
have been shown to disrupt FUT2 function but occur at low fre-
quencies; for example, the missense mutation C571T (rs180028) 
has a minor allele frequency of 0.1% globally [12].
For SNPs G428A, C302T, and A385T, functional alleles are 
hereafter labeled Se428, Se302, and Se385, respectively, while non-
functional alleles are labeled se428, se302, and se385. Individuals 
with 2 nonfunctional alleles at a given locus (eg, se428se428) 
will lack FUT2 activity, resulting in a nonsecretor phenotype. 
Moreover, owing to strong linkage disequilibrium between 
these SNPs, nonfunctional variants rarely co-occur on the 
same strand (full genotypic data from South Asians in the 1000 
Genomes Project are provided in Supplementary Table 1). Thus, 
individuals heterozygous at >1 locus (eg, Se428se428 and Se302se302) 
will also lack a functional copy of FUT2.
SNPs were assessed on a QuantStudio 7 Flex real-time 
PCR system, using TaqMan SNP genotyping assays (Applied 
Biosystems; assay identifiers C__2405292_10, C_190470442_10, 
and C__8832449_10), following the manufacturer’s instruc-
tions. Genotypes were assigned using TaqMan Genotyper soft-
ware (Applied Biosystems).
Statistical Analysis
For each locus in turn, we assessed the association between 
secretor status (secretor vs nonsecretor as a categorical inde-
pendent variable) and seroconversion via logistic regression. 
Infants were designated secretors if they had ≥1 functional 
allele (eg, Se428Se428 or Se428se428) and nonsecretors if they had 2 
nonfunctional alleles (se428se428). We also performed a combined 
analysis in which infants were designated as nonsecretors if they 
had 2 nonfunctional alleles at any locus (se428se428, se302se302, or 
se385se385) or if they were heterozygous at >1 locus (eg, Se428se428 
and Se302se302). In the subset of 109 infants for whom poliovi-
rus shedding was tested 7 days after vaccination (of whom 67 
[61%] were positive for poliovirus), we repeated the analysis 
with shedding as the outcome variable. Geometric mean titers 
of serum neutralizing antibodies were compared between secre-
tors and nonsecretors, using the Wilcoxon rank sum test, with 
values of 1/3 and 1/728 assigned to infants with values below 
and above the limits of the microneutralization dilution series 
(1/4 and 1/512, respectively). Analyses were performed in the 
programming language R.
RESULTS
Among the 260 infants included in this study, we successfully 
genotyped SNPs G428A, C302T, and A385T in 240 (92.3%); 
no amplification was observed for ≥1 SNP in the remaining 
samples. At SNP G428A, we observed the genotypes Se428Se428, 
Se428se428, and se428se428 in 147 (61.3%), 56 (23.3%), and 37 
(15.4%) infants, respectively. At SNP C302T, we observed 
the genotypes Se302Se302, Se302se302, and se302se302 in 194 infants 
(80.8%), 38 infants (15.8%), and 8 infants (3.3%), respectively. 
At SNP A385T, 239 of 240 infants (99.6%) had the genotype 
Se385Se385, and the remaining individual had the genotype 
Se385se385. Nine individuals (3.8%) were heterozygous at SNPs 
G428A and C302T and were designated nonsecretors.
We did not observe a significant association between FUT2 
genotype and seroconversion status (Table 1). Combining across 
loci, secretor genotypes were observed in 89 of 118 infants 
(75.4%) who seroconverted to type 3 poliovirus and 97 of 122 
infants (79.5%) who failed to seroconvert (odds ratio [OR], 
0.79; 95% confidence interval [CI], .43–1.45; logistic regression, 
P  =  .445). Geometric mean titers of serum neutralizing anti-
bodies 21 days after immunization were higher in nonsecretors 
than secretors, although this difference was not significant (19.2 
vs 15.2; Wilcoxon P  =  .195; Supplementary Figure  2). When 
considering postvaccination shedding as an outcome, we did 
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not observe a significant difference in secretor genotype preva-
lence between shedders and nonshedders (Table 1).
DISCUSSION
The secretion of HBGAs, as determined by FUT2, affects sus-
ceptibility to several enteric viruses. Although recent findings 
suggest that nonsecretors may be less likely to respond to oral 
rotavirus vaccine [5, 6], the same does not appear to be true 
of OPV. Among infants in south India—a population that has 
consistently been linked with impaired response to oral vac-
cines—the proportion of secretors did not differ significantly 
according to seroconversion or shedding status following a sin-
gle dose of mOPV3.
Notably, in the case of both rotavirus and norovirus, viral sur-
face proteins are known to bind HBGAs in a genotype-specific 
manner [13, 14]. It is likely that these interactions form the basis 
of discrepancies in susceptibility between secretors and non-se-
cretors. The extent to which polioviruses interact with HBGAs 
is unknown. However, poliovirus has been shown to bind lipo-
polysaccharide, and in vitro infectivity is enhanced by exposure 
to this bacterial surface molecule [15]. Thus, it appears that polio-
virus have evolved to exploit microbiota-derived signals during 
colonization of the intestinal mucosa, and may simply be indiffer-
ent to the presence or absence of HBGAs in mucosal secretions.
Our study has several limitations. First, we lacked the nec-
essary samples to directly assess whether HBGAs were present 
in mucosal secretions and have therefore inferred phenotype 
from genotype. However, previous studies have found SNPs 
G428A and C302T to be highly predictive of secretor phenotype 
[6, 10]. Second, HBGA-related genes other than FUT2, such as 
ABO and FUT3 (the Lewis gene), may also be pertinent to OPV 
outcome but were not considered here. Finally, we based our 
sample size calculations on a previous cohort study in Vellore in 
which one third of individuals were nonsecretors [8]. By contrast, 
we observed nonsecretor genotypes in 23% of infants. The allele 
frequencies at SNPs G428A, C302T, and A385T in this study were 
consistent with those observed among South Asians in the 1000 
Genomes Project [11, 12], and reasons for the discrepancy with 
previous findings from Vellore (including a significantly lower 
prevalence of the allele se385 in the present study) are unclear.
These caveats notwithstanding, our study is among the larg-
est to assess the association between FUT2 genotype and oral 
vaccine response. Our findings suggest that the locus may not 
be a key determinant of variation in OPV immunogenicity.
Supplementary Data
Supplementary materials are available at The Journal of Infectious 
Diseases online. Consisting of data provided by the authors to 
benefit the reader, the posted materials are not copyedited and 
are the sole responsibility of the authors, so questions or com-
ments should be addressed to the corresponding author.
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Table 1. Frequency of FUT2 Alleles and Inferred Phenotypes by Oral Poliovirus Vaccine (OPV) Response
SNP, Group
Seroconversion, No. (%) Shedding, No. (%)
Seronegative
(n = 122)
Seropositive
(n = 118) P
Nonshedder
(n = 49)
Shedder
(n = 60) P
G428A
 Se428Se428 or Se428se428 107 (87.7) 96 (81.4) .176 43 (87.8) 52 (86.7) .866
 se428se428 15 (12.3) 22 (18.6) 6 (12.2) 8 (13.3)
A385T
 Se385Se385 or Se385se385 122 (100) 118 (100) - 49 (100) 60 (100) -
G302T
 Se302Se302 or Se302se302 116 (95.1) 116 (98.3) .184 47 (95.9) 58 (96.7) .837
 se302se302 6 (4.9) 2 (1.7) 2 (4.1) 2 (3.3)
Combineda
 Secretor 97 (79.5) 89 (75.4) .449 39 (79.6) 47 (78.3) .873
 Nonsecretor 25 (20.5) 29 (24.6) 10 (20.4) 13 (21.7)
P values were determined via logistic regression with OPV outcome as the dependent variable. SNPs were not successfully genotyped in 20 of 260 infants included in this study (12 sero-
logical responders and 8 nonresponders).
Abbreviation: SNP, single-nucleotide polymorphism.
aInfants with the genotypes se428se428 and se302se302 were inferred to be nonsecretors, as were those with heterozygous genotypes at >1 locus (eg, Se428se428 and Se302se302).
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